TL have you just found the answer for the delay of the...

TL have you just found the answer for the delay of the announcement with the second largest mass market player.

If your theory is right and J+J having offloaded Janssen Pharmaceuticals (owner of Retin-A Micro for acne, Ertaczo for athlete’s foot and Renova, another acne treatment) as part of its ongoing efforts to restructure itself after a pretty ordinary time of it of late including 25 product recalls, is now to focus on lower risk (aka less prescription based) revenues which subsequently shifts focus to TPM - you may have just found the answer for the delay in the POH's announcement of the mass market player if this article has anything to do with it -

http://www.ftc.gov/os/caselist/1110216/111209valeantjjagree.pdf

Essentially the Janssen sale is being delayed by the federal trade commission. POH may just be under orders to hold off until the dust has settled before J+J roll with a new non-prescription based product.